Slide Source:Lipids Online Slide Librarywww.lipidsonline.org

DAIS Investigators. Lancet 2001;357:905-910.

DAIS: Baseline Lipid CharacteristicsDAIS: Baseline Lipid Characteristics

mean + SDTC TG LDL-C HDL-C

PlaceboPlacebo

FenofibrateFenofibrate

p = 0.033

mg/dL

0

177

354

531

TG

0

77

155

232

Chol

Slide Source:Lipids Online Slide Librarywww.lipidsonline.org

LDL-C

DAIS Investigators. Lancet 2001;357:905-910.Reprinted with permission from Elsevier Science.

DAIS: Mean Lipid ChangesDAIS: Mean Lipid Changes

TC TGHDL-C

PlaceboPlacebo

FenofibrateFenofibrate

Perc

en

t C

han

ge

10

0

-10

-20

-30

Slide Source:Lipids Online Slide Librarywww.lipidsonline.org

DAIS: Angiographic Changes from BaselineDAIS: Angiographic Changes from Baseline

Minimum lumendiameter

-0.10

-0.08

-0.06

-0.04

-0.02

0.00

-40%-40%

Percent Stenosis

-42%-42%

Mean Segment Diameter

-25%-25%

DAIS Investigators. Lancet 2001;357:905-910.

4.00

2.00

0.00

pp = 0.029 = 0.029 pp = 0.020 = 0.020 pp = 0.171 = 0.171

-0.10

-0.08

-0.06

-0.04

-0.02

0.00

mm%

change mm

Pro

gre

ssio

n o

f C

AD

Pro

gre

ssio

n o

f C

AD

Slide Source:Lipids Online Slide Librarywww.lipidsonline.org

DAIS: Combined Clinical EndpointsDAIS: Combined Clinical Endpoints

PlaceboPlacebo

FenofibrateFenofibrate

Event

Rate

25

20

15

10

5

0

-23%-23%**

38385050

* Number of participants with at least one clinical or interventional endpoint, including death, stroke, MI, CABG, PTCA and hospitalization for angina

*DAIS was not powered *DAIS was not powered to examine clinical to examine clinical events. Even though events. Even though the results suggest a the results suggest a trend, they were not trend, they were not statistically significantstatistically significant

DAIS Investigators. Lancet 2001;357:905-910.